Выбор редакции

Shares of BioLineRX ([[BLRX]] -15%) tank after the drug developer repeats its plan to report interim results from Phase II/III testing of its acute schizophrenia treatment BL-1020 during the week of March 18, amid speculation of less-than-stellar results. The interim analysis will be performed by a fully independent, external Data Monitoring Committee.

Shares of BioLineRX (BLRX -15%) tank after the drug developer repeats its plan to report interim results from Phase II/III testing of its acute schizophrenia treatment BL-1020 during the week of March 18, amid speculation of less-than-stellar results. The interim analysis will be performed by a fully independent, external Data Monitoring Committee. 1 comment!

НОВОСТИ ПО ТЕМЕ